Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.46 |
| ▸ | CES1 | P23141 | 2/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.38 |
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3956655 | 0.75 | TSHR (0.46) | TAAR1DPP4F2TSHRHTR2A | |
| SCHEMBL2048984 | 0.74 | CES2 (0.41) | CES2CES1TRPA1DPP4F2 | |
| SCHEMBL2320123 | 0.72 | DPP4 (0.41) | TAAR1DPP4F2TSHRHTR2A | |
| SCHEMBL3484529 | 0.72 | CES2 (0.44) | CES2CES1TRPA1DPP4F2 | |
| SCHEMBL1575568 | 0.70 | TSHR (0.52) | TAAR1DPP4F2TSHRHTR2A | |
| SCHEMBL1145689 | 0.70 | KMT2A (0.44) | TAAR1DPP4F2TSHRLMNA | |
| SCHEMBL20809867 | 0.70 | KMT2A (0.44) | TAAR1DPP4F2TSHRLMNA | |
| SCHEMBL14535430 | 0.70 | KMT2A (0.44) | TAAR1DPP4F2TSHRLMNA | |
| SCHEMBL11444420 | 0.70 | CES2 (0.43) | CES2CES1TRPA1TAAR1DPP4 | |
| SCHEMBL28780351 | 0.70 | TAAR1 (0.40) | CES2CES1TRPA1TAAR1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111954848-B | Photosensitive resin composition, cured product, insulating material, resin material for solder resist, and resist member | DIC株式会社 | 2024-05-03 | — | — | CN | disclosed |
| CN-109153653-B | Novel compound, photocurable composition, cured product thereof, printing ink, and printed matter using the printing ink | DIC株式会社 | 2022-06-28 | — | — | CN | disclosed |
| US-11079675-B2 | Compound, photocurable composition, cured product of same, printing ink, and printed matter curing the printing ink | DIC CORPORATION (JP) | 2021-08-03 | — | — | US | disclosed |
| CN-111954848-A | Photosensitive resin composition, cured product, insulating material, resin material for solder resist, and resist member | DIC株式会社 | 2020-11-17 | — | — | CN | disclosed |
| WO-2019198490-A1 | PHOTOSENSITIVE RESIN COMPOSITION, CURED PRODUCT, INSULATING MATERIAL, RESIN MATERIAL FOR SOLDER RESISTS AND RESIST MEMBER | DIC株式会社 | 2019-10-17 | — | — | WO | disclosed |
| US-20190137872-A1 | NOVEL COMPOUND, PHOTOCURABLE COMPOSITION, CURED PRODUCT OF SAME, PRINTING INK, AND PRINTED MATTER SURING THE PRINTING INK | DIC CORPORATION (JP) | 2019-05-09 | — | — | US | disclosed |
| US-20090221640-A1 | Novel Crystal Modifications | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
| EP-2064202-A2 | A NEW CRYSTALLINE FORM G OF (5S)-5-[4-(5-CHLORO-PYRIDIN-2-YLOXY)-PIPERIDINE-1-SULFONYL-METHYL]-5-METHYL-IMIDAZOLIDINE-2,4-DIONE (I) AND INTERMEDIATES THEREOF. | AstraZeneca AB (SE) | 2009-06-03 | — | — | EP | disclosed |
| CN-101448819-A | A new crystalline form g of (5s)-5-[4-(5-chloro-pyridin-2-yloxy)-piperidine-1-sulfonylmethyl]-5-methyl-imidazolidine-2,4-dione (i) and intermediates thereof | ASTRAZENECA AB (SE) | 2009-06-03 | — | — | CN | disclosed |
| WO-2007106022-A2 | A NEW CRYSTALLINE FORM G OF (5S) -5- [4- (5-CHLORO-PYRIDIN-2- YLOXY) -PIPERIDINE-1-SULFONYLMETHYL] - 5 -METHYL -IMIDAZOLIDINE - 2,4-DIONE (I) AND INTERMEDIATES THEREOF. | ASTRAZENECA AB (SE) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11079675-B2 | Compound, photocurable composition, cured product of same, printing ink, and printed matter curing the printing ink | EPB41, F12, CDK1 | CES2 1235/4885CES1 2811/4885TRPA1 678/4885 |
| US-20190137872-A1 | NOVEL COMPOUND, PHOTOCURABLE COMPOSITION, CURED PRODUCT OF SAME, PRINTING INK, AND PRINTED MATTER SURING THE PRINTING INK | EPB41, CDK1, CDKN1A | CES2 769/4885CES1 2260/4885TRPA1 492/4885 |
| US-20090221640-A1 | Novel Crystal Modifications | PTMS, NT5C, CDK5 | CES2 1467/4885CES1 3810/4885TRPA1 4844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.